BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

INTRODUCTION: BAY 94‐9027 is an extended‒half‐life, site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII). The PROTECT VIII main study demonstrated efficacy of bleed control using extended‐interval prophylaxis with BAY 94‐9027 for 36 weeks. AIM: To report long‐term efficacy a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haemophilia
Main Authors: Lalezari, Shadan, Reding, Mark T., Pabinger, Ingrid, Holme, Pal Andre, Negrier, Claude, Chalasani, Pavani, Shin, Ho‐Jin, Wang, Maria, Tseneklidou‐Stoeter, Despina, Maas Enriquez, Monika
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6900134/
https://ncbi.nlm.nih.gov/pubmed/31621991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.13853
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados